FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people
Publishing timestamp: 2023-03-16 17:19:18
Summary
FDA's independent panel of advisors recommended full approval of Pfizer's Covid antiviral treatment Paxlovid for high-risk adults, but flagged potentially harmful drug interactions. The treatment is advised for people over 50 or those who suffer from medical conditions such as high blood pressure or diabetes that place them at higher risk of ending up in hospital or dying from Covid. The FDA is slated to make a final decision in May.
Sentiment: NEUTRAL
Tickers: PFE,
Keywords: joe biden, biotechnology, health care industry, business news, pharmaceuticals, fda, breaking news, pfizer inc, business, biotech and pharmaceuticals, breaking news: business, anthony fauci, covid-19, coronavirus, centers for disease control and prevention,